Constitutive Fms-like tyrosine kinase 3 activation results in specific changes in gene expression in myeloid leukaemic cells

被引:34
作者
Kim, Kyu-Tae
Baird, Kristin
Davis, Sean
Piloto, Obdulio
Levis, Mark
Li, Li
Chen, Peili
Meltzer, Paul
Small, Donald
机构
[1] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21218 USA
[2] NIH, NCI, Canc Res Ctr, Genet Branch, Bethesda, MD 20892 USA
关键词
Fms-like tyrosine kinase 3; internal tandem duplication; acute myeloid leukaemia; gene expression profile;
D O I
10.1111/j.1365-2141.2007.06696.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Constitutively activating internal tandem duplication (ITD) mutations of the receptor tyrosine kinase FLT3 (Fms-like tyrosine kinase 3) play an important role in leukaemogenesis. We have examined, by cDNA microarray analysis, the changes in gene expression induced by FLT3/ITD or constitutively activated wild type FLT3 signalling. A limited set of genes was consistently affected by FLT3 inhibition. In confirmation of their FLT3 dependence, these genes returned toward pretreatment levels of expression after reversal of FLT3 inhibition. Several of the most significantly affected genes are involved in the RAS/mitogen-activated protein kinase, Janus kinase/signal transducer and activator of transcription and phosphatidylinositol 3 kinase (PI3K)/AKT pathways. These data suggest that constitutively activated FLT3 works through multiple signal transduction pathways. PIM1, MYC and CCND3 were chosen from this gene set to explore their biological roles. Knock-down of these genes by small interfering RNA showed that these genes play important roles in constitutively activated FLT3 expressing cells. The alterations of the gene expression profiles in these cells help to further elucidate the mechanisms of FLT3-mediated leukaemogenesis.
引用
收藏
页码:603 / 615
页数:13
相关论文
共 44 条
[1]  
Bai M, 2003, HISTOL HISTOPATHOL, V18, P449, DOI 10.14670/HH-18.449
[2]  
BIRG F, 1992, BLOOD, V80, P2584
[3]   Adult Burkitt leukemia and lymphoma [J].
Blum, KA ;
Lozanski, G ;
Byrd, JC .
BLOOD, 2004, 104 (10) :3009-3020
[4]   Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias [J].
Carow, CE ;
Levenstein, M ;
Kaufmann, SH ;
Chen, J ;
Amin, S ;
Rockwell, P ;
Witte, L ;
Borowitz, MJ ;
Civin, CI ;
Small, D .
BLOOD, 1996, 87 (03) :1089-1096
[5]   TYROSINE KINASE ONCOGENES ABROGATE INTERLEUKIN-3 DEPENDENCE OF MURINE MYELOID CELLS THROUGH SIGNALING PATHWAYS INVOLVING C-MYC - CONDITIONAL REGULATION OF C-MYC TRANSCRIPTION BY TEMPERATURE-SENSITIVE V-ABL [J].
CLEVELAND, JL ;
DEAN, M ;
ROSENBERG, N ;
WANG, JYJ ;
RAPP, UR .
MOLECULAR AND CELLULAR BIOLOGY, 1989, 9 (12) :5685-5695
[6]  
DeRisi J, 1996, NAT GENET, V14, P457
[7]   Delineation of prognostic biomarkers in prostate cancer [J].
Dhanasekaran, SM ;
Barrette, TR ;
Ghosh, D ;
Shah, R ;
Varambally, S ;
Kurachi, K ;
Pienta, KJ ;
Rubin, MA ;
Chinnaiyan, AM .
NATURE, 2001, 412 (6849) :822-826
[8]  
Fenski R, 2000, BRIT J HAEMATOL, V108, P322
[9]   The roles of FLT3 in hematopoiesis and leukemia [J].
Gilliland, DG ;
Griffin, JD .
BLOOD, 2002, 100 (05) :1532-1542
[10]   Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].
Gorre, ME ;
Mohammed, M ;
Ellwood, K ;
Hsu, N ;
Paquette, R ;
Rao, PN ;
Sawyers, CL .
SCIENCE, 2001, 293 (5531) :876-880